ArticleBreast care (Basel, Switzerland)2022

Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level.

Michael Braun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.